Literature DB >> 8791964

Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.

M Hartmann1, U Theiss, R Huber, R Lühmann, H Bliesath, W Wurst, P W Lücker.   

Abstract

BACKGROUND: Pantoprazole is a proton pump inhibitor characterized by a low potential to interact with the cytochrome P450 enzyme system in man. Its effect on intragastric pH following single and repeated oral intake was investigated in comparison to omeprazole by continuous intragastric pH-metry at doses recommended for treatment of peptic ulcer disease.
METHODS: Sixteen healthy male subjects underwent two dosing periods. From day 1 to day 7, they were given once daily by mouth 40 mg pantoprazole in one period and 20 mg omeprazole in the other period, according to a double-blind randomized crossover design. Twenty-four-hour intragastric pH was recorded and frequent blood samples for pharmacokinetic analysis were taken on day 1 and day 7. A placebo pH profile was obtained prior to each treatment period.
RESULTS: Pantoprazole was significantly more effective than omeprazole with regard to increase in 24-h and daytime pH, following both single (median 24-h pH: 1.45 vs. 1.3, P < 0.05; median daytime pH: 1.6 vs. 1.3, P < 0.01) and repeated (median 24-h pH: 3.15 vs. 2.05, P < 0.01; median daytime pH: 3.8 vs. 2.65, P < 0.05) oral intake. As compared to the first dose, repeated administration of both drugs markedly increased the effect on intragastric pH. With pantoprazole, steady-state serum concentrations were obtained after the first dose, but not with omeprazole. Both drugs were well tolerated without relevant changes in vital signs of clinical laboratory parameters.
CONCLUSION: Pantoprazole 40 mg is significantly more effective than omeprazole 20 mg in raising intragastric pH.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8791964     DOI: 10.1111/j.0953-0673.1996.00359.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  21 in total

1.  Measurement of postprandial changes in urine acid output to detect changes of gastric acid secretion after proton pump inhibitors in children.

Authors:  Giuseppina Oderda; Anna Rapa; Elena Chiorboli; Barbara Ronchi; Annalisa Zavallone; Laura Strigini
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

Review 2.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.

Authors:  Vijaya S Pratha; Daniel L Hogan; James R Lane; Paul J Williams; Michael S Burton; Richard B Lynn; Robyn G Karlstadt
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

4.  Comparative bioavailability study of two oral omeprazole formulations after single and repeated administrations in healthy volunteers.

Authors:  T Duvauchelle; L Millerioux; V Gualano; E Evene; A Alcaide
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 5.  Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.

Authors:  Desmond Padhi; Robert Harris
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 6.  Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.

Authors:  Susan M Cheer; Amitabh Prakash; Diana Faulds; Harriet M Lamb
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?

Authors:  Alexander L Fohl; Randolph E Regal
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-06-06

8.  Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects.

Authors:  Hui-Wen Jiao; Lu-Ning Sun; Yue-Qi Li; Lei Yu; Hong-Wen Zhang; Mei-Feng Wang; Li-Yuan Yu; Zi-Qing-Yun Yuan; Li-Jun Xie; Juan Chen; Ling Meng; Xue-Hui Zhang; Yong-Qing Wang
Journal:  Eur J Clin Pharmacol       Date:  2017-11-22       Impact factor: 2.953

Review 9.  Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.

Authors:  A Fitton; L Wiseman
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

10.  No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.

Authors:  Olesja Rissling; Petra Glander; Pia Hambach; Marco Mai; Susanne Brakemeier; Daniela Klonower; Fabian Halleck; Eugenia Singer; Eva-Vanessa Schrezenmeier; Michael Dürr; Hans-Hellmut Neumayer; Klemens Budde
Journal:  Br J Clin Pharmacol       Date:  2015-07-14       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.